OBJECTIVE: Increased risk of cancer and other adult diseases have been associated with perinatal exposure to adverse conditions such as stress and famine. Recently, Insulin-like growth factor II (IGF-II) was identified as the first gene associated with altered expression caused by fetal exposure to poor nutrition. IGF-II regulates fetal development and breast cancer cell survival, in part, by regulating anti-apoptotic proteins through activation of the IGF-I and insulin receptors. African-American (AA) women have a lower overall breast cancer (BC) incidence, however, they present with advanced disease at diagnosis, poorer prognosis and lower survival than Caucasian (CA) women. The reasons for the BC survival disparity are not well understood. We hypothesize that IGF-II plays a role in the survival disparity observed among AA breast cancer patients by stimulating rapid tumor growth, inhibiting apoptosis, and promoting metastasis. DESIGN: This study examines IGF-II expression and regulation of the anti-apoptotic proteins Bcl-2, Bcl-X(L), and survivin in Hs578t (ER-), CRL 2335 (ER-), and CRL 2329 (ER+) breast cancer cells and compares with the expression of these proteins in paired breast tissue samples from AA and CA women by qRT-PCR and Western blotting. RESULTS: IGF-II expression was significantly higher in AA cell lines and tissue samples when compared to Caucasians. IGF-II siRNA treatment decreased anti-apoptotic protein levels in all cell lines (regardless of ER status). These effects were blocked by the addition of recombinant IGF-II. Of significance, IGF-II expression and regulation of Bcl-X(L) and survivin in cell lines correlated with their expression in paired breast tissues. CONCLUSIONS: IGF-II and the anti-apoptotic proteins differential expression among AA and CA patients may contribute to the breast cancer survival disparities observed between these ethnic groups. Copyright (c) 2009. Published by Elsevier Ltd.
OBJECTIVE: Increased risk of cancer and other adult diseases have been associated with perinatal exposure to adverse conditions such as stress and famine. Recently, Insulin-like growth factor II (IGF-II) was identified as the first gene associated with altered expression caused by fetal exposure to poor nutrition. IGF-II regulates fetal development and breast cancer cell survival, in part, by regulating anti-apoptotic proteins through activation of the IGF-I and insulin receptors. African-American (AA) women have a lower overall breast cancer (BC) incidence, however, they present with advanced disease at diagnosis, poorer prognosis and lower survival than Caucasian (CA) women. The reasons for the BC survival disparity are not well understood. We hypothesize that IGF-II plays a role in the survival disparity observed among AA breast cancerpatients by stimulating rapid tumor growth, inhibiting apoptosis, and promoting metastasis. DESIGN: This study examines IGF-II expression and regulation of the anti-apoptotic proteins Bcl-2, Bcl-X(L), and survivin in Hs578t (ER-), CRL 2335 (ER-), and CRL 2329 (ER+) breast cancer cells and compares with the expression of these proteins in paired breast tissue samples from AA and CA women by qRT-PCR and Western blotting. RESULTS:IGF-II expression was significantly higher in AA cell lines and tissue samples when compared to Caucasians. IGF-II siRNA treatment decreased anti-apoptotic protein levels in all cell lines (regardless of ER status). These effects were blocked by the addition of recombinant IGF-II. Of significance, IGF-II expression and regulation of Bcl-X(L) and survivin in cell lines correlated with their expression in paired breast tissues. CONCLUSIONS:IGF-II and the anti-apoptotic proteins differential expression among AA and CA patients may contribute to the breast cancer survival disparities observed between these ethnic groups. Copyright (c) 2009. Published by Elsevier Ltd.
Authors: Susanne K Pedersen; Jan Christiansen; Thomas v O Hansen; Martin R Larsen; Finn C Nielsen Journal: Biochem J Date: 2002-04-01 Impact factor: 3.857
Authors: A Morrione; B Valentinis; S Q Xu; G Yumet; A Louvi; A Efstratiadis; R Baserga Journal: Proc Natl Acad Sci U S A Date: 1997-04-15 Impact factor: 11.205
Authors: Alessandra Giodini; Marko J Kallio; Nathan R Wall; Gary J Gorbsky; Simona Tognin; Pier Carlo Marchisio; Marc Symons; Dario C Altieri Journal: Cancer Res Date: 2002-05-01 Impact factor: 12.701
Authors: Laura España; Yolanda Fernández; Nuria Rubio; Angels Torregrosa; Jeronimo Blanco; Angels Sierra Journal: Breast Cancer Res Treat Date: 2004-09 Impact factor: 4.872
Authors: Lina Mu; Dionyssios Katsaros; Andrew Wiley; Lingeng Lu; Irene A Rigault de la Longrais; Stephanie Smith; Sapna Khubchandani; Olga Sochirca; Riccardo Arisio; Herbert Yu Journal: Breast Cancer Res Treat Date: 2008-05-15 Impact factor: 4.872
Authors: Anamika Basu; Hiya Banerjee; Heather Rojas; Shannalee R Martinez; Sourav Roy; Zhenyu Jia; Michael B Lilly; Marino De León; Carlos A Casiano Journal: Prostate Date: 2010-10-28 Impact factor: 4.104
Authors: Nalo Hamilton; Diana Marquez-Garban; Vei H Mah; Yahya Elshimali; David Elashoff; Edward B Garon; Jaydutt Vadgama; Richard Pietras Journal: Crit Rev Oncog Date: 2015
Authors: Xu You Liu; Shao Hui Tang; Sheng Lan Wu; Yu Hong Luo; Ming Rong Cao; Hong Ke Zhou; Xiang Wu Jiang; Jian Chang Shu; Cai Qun Bie; Si Min Huang; Zhan Hong Zheng; Fei Gao Journal: Am J Cancer Res Date: 2015-02-15 Impact factor: 6.166
Authors: Salma Khan; Heather Ferguson Bennit; Malyn May Asuncion Valenzuela; David Turay; Carlos J Diaz Osterman; Ron B Moyron; Grace E Esebanmen; Arjun Ashok; Nathan R Wall Journal: Biologics Date: 2015-07-09